{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:14:41Z","timestamp":1790046881193,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ijcha.2024.101526","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T18:01:42Z","timestamp":1729447302000},"page":"101526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Breaking boundaries: Ticagrelor monotherapy in high-risk patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Balbir","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshava","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafulla","family":"Kerkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasant","family":"Kumar Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Kumar Premchand Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvanan","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Sarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijcha.2024.101526_b0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.31083\/j.rcm2202044","article-title":"Ticagrelor: Clinical development and future potential","volume":"22","author":"Sanderson","year":"2021","journal-title":"Rev. Cardiovasc Med."},{"issue":"23","key":"10.1016\/j.ijcha.2024.101526_b0010","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.ijcha.2024.101526_b0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101526_b0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: Emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat. Rev. Cardiol"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101526_b0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization [published correction appears in Eur Heart J 2019 Oct 1;40(37):3096]","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ijcha.2024.101526_b0030","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5603\/KP.2017.0224","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"75","author":"Valgimigli","year":"2017","journal-title":"Pol. Heart J."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101526_b0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101526_b0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101526_b0045","doi-asserted-by":"crossref","first-page":"e017008","DOI":"10.1161\/JAHA.120.017008","article-title":"Predictors, type, and impact of bleeding on the net clinical benefit of long-term ticagrelor in stable patients with prior myocardial infarction","volume":"10","author":"Magnani","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"17","key":"10.1016\/j.ijcha.2024.101526_b0050","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101526_b0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2020.12.005","article-title":"Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: Analysis from ADAPT-DES","volume":"14","author":"Chau","year":"2021","journal-title":"JACC Cardiovasc Interv."},{"key":"10.1016\/j.ijcha.2024.101526_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.ijcha.2024.101526_b0065","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J. Am. Coll. Cardiol"},{"issue":"38","key":"10.1016\/j.ijcha.2024.101526_b0070","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.ijcha.2024.101526_b0075","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl J. Med."},{"issue":"12","key":"10.1016\/j.ijcha.2024.101526_b0080","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2020.06.085","article-title":"Trial design principles for patients at high bleeding risk undergoing PCI: JACC scientific expert panel","volume":"76","author":"Capodanno","year":"2020","journal-title":"J. Am. Coll Cardiol"},{"key":"10.1016\/j.ijcha.2024.101526_b0085","doi-asserted-by":"crossref","unstructured":"van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur. Heart J. 42(10) (2021) 1038-1046. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1097.","DOI":"10.1093\/eurheartj\/ehaa1097"},{"key":"10.1016\/j.ijcha.2024.101526_b0090","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): An investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ijcha.2024.101526_b0095","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijcha.2024.101526_b0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2021.03.053","article-title":"P2Y12 Inhibitor monotherapy versus conventional dual antiplatelet therapy or aspirin monotherapy in acute coronary syndrome: A pooled analysis of the SMART-DATE and SMART-CHOICE trials","volume":"150","author":"Song","year":"2021","journal-title":"Am. J. Cardiol"},{"issue":"10308","key":"10.1016\/j.ijcha.2024.101526_b0105","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): An investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"issue":"10127","key":"10.1016\/j.ijcha.2024.101526_b0110","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): A randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"issue":"k3793","key":"10.1016\/j.ijcha.2024.101526_b0115","first-page":"1","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): Randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ijcha.2024.101526_b0120","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101526_b0125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101526_b0130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ihj.2014.08.012","article-title":"Clopidogrel resistance: The way forward","volume":"66","author":"Ray","year":"2014","journal-title":"Indian Heart J."},{"issue":"2","key":"10.1016\/j.ijcha.2024.101526_b0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5469\/neuroint.2019.00087","article-title":"Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience","volume":"14","author":"Karan","year":"2019","journal-title":"Neurointervention"},{"issue":"12","key":"10.1016\/j.ijcha.2024.101526_b0140","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: A Consensus Statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat. Rev. Cardiol"},{"issue":"17","key":"10.1016\/j.ijcha.2024.101526_b0145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A Genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J. Med."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101526_b0150","doi-asserted-by":"crossref","first-page":"e024159","DOI":"10.1161\/JAHA.121.024159","article-title":"CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings","volume":"11","author":"Beitelshees","year":"2022","journal-title":"J. Am. Heart Assoc"},{"issue":"10439","key":"10.1016\/j.ijcha.2024.101526_b0155","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ijcha.2024.101526_b0160","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ijcha.2024.101526_b0165","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jcin.2021.04.043","article-title":"Impact of age on the safety and efficacy of ticagrelor monotherapy in patients undergoing PCI","volume":"14","author":"Angiolillo","year":"2021","journal-title":"JACC Cardiovasc Interv."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101526_b0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcin.2021.11.005","article-title":"Ticagrelor monotherapy after PCI in high-risk patients with prior MI: a prespecified TWILIGHT Substudy","volume":"15","author":"Chiarito","year":"2022","journal-title":"JACC Cardiovasc Interv."},{"issue":"19","key":"10.1016\/j.ijcha.2024.101526_b0175","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J. Am. Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101526_b0180","first-page":"63","article-title":"Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY","volume":"97","author":"Baber","year":"2021","journal-title":"Catheter Cardiovasc Interv."},{"issue":"45","key":"10.1016\/j.ijcha.2024.101526_b0185","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.ijcha.2024.101526_b0190","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.4244\/EIJ-D-21-00721","article-title":"Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: The TWILIGHT-STENT study","volume":"17","author":"Dangas","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcha.2024.101526_b0195","doi-asserted-by":"crossref","unstructured":"Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur. Heart J. 41(37) (2020) 3533-3545. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa670.","DOI":"10.1093\/eurheartj\/ehaa670"},{"issue":"23","key":"10.1016\/j.ijcha.2024.101526_b0200","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijcha.2024.101526_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.620906","article-title":"Ischemic and bleeding events of ticagrelor monotherapy in korean patients with and without diabetes mellitus: Insights from the TICO trial","volume":"11","author":"Yun","year":"2021","journal-title":"Front Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101526_b0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcin.2020.11.036","article-title":"Ticagrelor monotherapy versus ticagrelor with aspirin in patients with ST-segment elevation myocardial infarction","volume":"14","author":"Lee","year":"2021","journal-title":"JACC Cardiovasc Interv."},{"key":"10.1016\/j.ijcha.2024.101526_b0215","doi-asserted-by":"crossref","unstructured":"Hong SJ, Lee SJ, Suh Y, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: The T-PASS randomized noninferiority trial. Circulation Published online October 25, 2023. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066943.","DOI":"10.1161\/CIRCULATIONAHA.123.066943"},{"key":"10.1016\/j.ijcha.2024.101526_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2020.09.057","article-title":"Safety and efficacy of 1-month dual antiplatelet therapy (ticagrelor + aspirin) followed by 23-month ticagrelor monotherapy in patients undergoing staged percutaneous coronary intervention (A sub-study from GLOBAL LEADERS)","volume":"138","author":"Kawashima","year":"2021","journal-title":"Am. J. Cardiol"},{"issue":"16","key":"10.1016\/j.ijcha.2024.101526_b0225","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.jacc.2019.08.997","article-title":"Efficacy and safety of ticagrelor monotherapy in patients undergoing multivessel PCI","volume":"74","author":"Takahashi","year":"2019","journal-title":"J. Am. Coll Cardiol"},{"issue":"31","key":"10.1016\/j.ijcha.2024.101526_b0230","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehz453","article-title":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: Insights from the Global Leaders trial","volume":"40","author":"Serruys","year":"2019","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.ijcha.2024.101526_b0235","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J. Am. Coll Cardiol"},{"issue":"19","key":"10.1016\/j.ijcha.2024.101526_b0240","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","article-title":"Ticagrelor with or without aspirin after complex PCI","volume":"75","author":"Dangas","year":"2020","journal-title":"J. Am. Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ijcha.2024.101526_b0245","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jamacardio.2021.1720","article-title":"Sex differences among patients with high risk receiving ticagrelor with or without aspirin after percutaneous coronary intervention: A subgroup analysis of the TWILIGHT randomized clinical trial","volume":"6","author":"Vogel","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.ijcha.2024.101526_b0250","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.jcin.2022.07.039","article-title":"Bleeding and ischemic outcomes with ticagrelor monotherapy according to body mass index","volume":"15","author":"Kunadian","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.ijcha.2024.101526_b0255","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jacc.2023.05.062","article-title":"Bleeding and ischemic risks of ticagrelor monotherapy after coronary interventions","volume":"82","author":"Mendieta","year":"2023","journal-title":"J. Am. Coll Cardiol"},{"issue":"10151","key":"10.1016\/j.ijcha.2024.101526_b0260","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2024.101526_b0265","series-title":"P2Y12 inhibitor or aspirin monotherapy as secondary prevention in patients with coronary artery disease: An individual participant data meta-analysis of randomized controlled trail","author":"Valgimigli","year":"2022"},{"issue":"22","key":"10.1016\/j.ijcha.2024.101526_b0270","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jacc.2019.03.011","article-title":"Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial","volume":"73","author":"Berwanger","year":"2019","journal-title":"J. Am. Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ijcha.2024.101526_b0275","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/jcph.2239","article-title":"A comparative study on ticagrelor and clopidogrel in patients with acute coronary syndrome treated with primary percutaneous coronary intervention","volume":"63","author":"Wu","year":"2023","journal-title":"J. Clin Pharmacol"},{"key":"10.1016\/j.ijcha.2024.101526_b0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.amjcard.2023.10.046","article-title":"Comparison of ticagrelor and clopidogrel in patients with acute coronary syndrome at high bleeding or ischemic risk","volume":"210","author":"Akyuz","year":"2024","journal-title":"Am. J. Cardiol"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101526_b0285","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt.2226","article-title":"Efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention: A meta-Analysis","volume":"110","author":"Gelbenegger","year":"2021","journal-title":"Clin. Pharmacol Ther."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101526_b0290","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jcin.2020.11.046","article-title":"Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: An individual patient-level meta-analysis","volume":"14","author":"Valgimigli","year":"2021","journal-title":"JACC Cardiovasc Interv."},{"issue":"20","key":"10.1016\/j.ijcha.2024.101526_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000026070","article-title":"Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis","volume":"100","author":"Zhang","year":"2021","journal-title":"Medicine (baltimore)"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:17:57Z","timestamp":1762622277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724001921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"alternative-id":["S2352906724001921"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101526","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking boundaries: Ticagrelor monotherapy in high-risk patients","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101526"}}